Business Trip

Feb 25 2025 57 ep. 47 mins 36
Business Trip Podcast artwork

Business Trip tells the story of businesses at the frontier of mental health and brain health. Each episode features founders, investors, and researchers in psychedelics, neurotechnology, metabolic psychiatry, digital therapeutics, and more. 

  Health & Fitness  Science
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Frontier investable areas in brain health with PsyMed Ventures

Feb 25 2025 49 mins  
Greg and Matias sit down with Brooks Leitner, the newest venture partner at PsyMed Ventures, to explore the future of brain and mental health investing. Brooks, an MD/PhD with deep experience from Yale and the NIH, shares his insights on how a human-first approach is reshaping neuroscience innovation and venture investing. In this episode, we discuss: Broadening the Thesis: Evolvin

Temporal Interference: The Future of Brain Stimulation with Nir Grossman

Jan 30 2025 22 mins  
Greg and Matias interview Dr. Nir Grossman, one of the world’s leading researchers in neurotechnology. Nir is a lecturer in the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute. In this episode, we discuss: What is temporal interference (TI), a non-invasive stimulation methodA comparison of TI with deep brain stim

The State of Autism Part 2 with James Adams of Gut-Brain-Axis Therapeutics Inc.

Dec 26 2024 40 mins  
Greg and Matias interview Dr. James Adams, professor and autism researcher at Arizona State University and President of Gut-Brain-Axis Therapeutics, on groundbreaking research in autism. In this episode, we discuss: The latest advancements in microbiome therapy for autismHow the gut-brain axis is shaping new therapeutic approachesThe role of nutritional interventions in supporting

The State of Autism Part 1 with Elizabeth Horn of 2m Foundation

Dec 12 2024 37 mins  
Matias interviews Elizabeth Horn, founder of the 2m Foundation, on the current state of autism and what can we do about it. In this episode, we discuss: The rising prevalence of autism and its impact on societyHow 2m Foundation is funding research and solutionsEnvironmental and biological factors contributing to autismPhilanthropy and venture capital through the Autism Impact FundC

Genetic Medicine for Brain Health with Dana Watt of Breakout Ventures

Nov 14 2024 44 mins  
Greg and Matias interview Dana Watt, a Partner at Breakout Ventures, about genetic medicine for brain and mental health. In this episode, we discuss: How genetic therapies work: addressing underlying causes, not just symptomsThe opportunities and challenges for genetic therapies for brain healthExploring effective delivery of genetic payloadsCommercial viability and insurance consi

Transcranial Focused Ultrasound for Mental Health with Jay Sanguinetti of Sanmai

Sep 05 2024 59 mins  
Greg and Matias interview Jay Sanguinetti, founder of Sanmai Technologies, a startup using transcranial focused ultrasound for the treatment of mental health conditions. Jay has a background in academia, having worked at the University of Arizona and started the SEMA Lab (Science Enhanced Mindful Awareness). In this episode, we discuss: The science behind transcranial focused ultra

Navigating FDA clinical trials in Neurotech with Tim Marjenin

Aug 23 2024 41 mins  
Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices. Tim provides insights into the FDA approval process for neurotech devices, drawing from his extensive experience on the FDA's Neurostimulation-Neurology Devices Team. The episode explores the evolving field

Environmental Toxins and Mental Health with Gurdane Bhutani

Jul 18 2024 49 mins  
Greg and Matias interview Gurdane Bhutani, an investor at MBX Ventures, to discuss the impact of environmental toxins on health and the field of exposomics. Gurdane is an expert in environmental health, with a background in Epidemiology and Environmental Health Sciences. He provided insights into the pervasive nature of environmental toxins and their implications for public health.

FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

Jun 21 2024 56 mins  
Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD. Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting. In this episode, we discuss: The FDA advisory com

Investing in New Frontiers of Mental Health (Live at SXSW)

May 07 2024 50 mins  
Software, hardware, and biotechnology are playing an increasingly transformative role in our mental health and wellness. Join us as we discuss what investors look for in these new companies and how they separate what’s real — and what’s near-term — from what’s hype. We’ll explore AI-powered tools for mental health, the new area of “enerceuticals” (energy replacing t